Ingevity Corp Reports Q2 2025 Net Loss of $146.5M Amid 7% Sales Decline; Adjusted EPS Rises 38%

Reuters
08-05
Ingevity Corp Reports <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Net Loss of $146.5M Amid 7% Sales Decline; Adjusted EPS Rises 38%

Ingevity Corporation reported its financial results for the second quarter of 2025, showing a 7% decline in net sales to $365.1 million, primarily due to reduced sales in the Performance Chemicals segment. The company experienced a net loss of $146.5 million, largely impacted by a pre-tax non-cash goodwill impairment charge of $183.8 million related to the Advanced Polymer Technologies segment. This charge was attributed to heightened global trade uncertainty and its effect on industrial demand recovery forecasts. Adjusted earnings increased 39% to $51.1 million, while adjusted EBITDA rose by 9% to $110.0 million, with the EBITDA margin improving to 30.1%. These improvements were mainly due to successful repositioning actions in the Performance Chemicals segment, which led to reduced raw material costs and a better product mix. Ingevity has updated its guidance, raising the low-end of its adjusted EBITDA forecast to between $390 million and $415 million, reflecting solid results and improved expectations for North American auto production. The company maintains its full-year sales guidance of between $1.25 billion and $1.40 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ingevity Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250804872946) on August 04, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10